{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:18:44Z","timestamp":1792703924448,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41591-024-03025-3","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T16:01:54Z","timestamp":1717689714000},"page":"2216-2223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-7200","authenticated-orcid":false,"given":"Roger","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paras H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler F.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Kil","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Lamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Uchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Geynisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5444-5510","authenticated-orcid":false,"given":"Joshua J.","family":"Meeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rian","family":"Dickstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane M.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Ho","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Il","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3546-9928","authenticated-orcid":false,"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk A.","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"3025_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","volume":"84","author":"I Jubber","year":"2023","unstructured":"Jubber, I. et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur. Urol. 84, 176\u2013190 (2023).","journal-title":"Eur. Urol."},{"key":"3025_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3233\/BLC-190236","volume":"5","author":"JR Mirabal","year":"2019","unstructured":"Mirabal, J. R., Taylor, J. A. & Lerner, S. P. CIS of the bladder: significance and implications for therapy. Bladder Cancer 5, 193\u2013204 (2019).","journal-title":"Bladder Cancer"},{"key":"3025_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo, N. et al. Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette\u2013Gu\u00e9rin. Eur. Urol. Oncol. 5, 84\u201391 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"3025_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","volume":"33","author":"W Martin-Doyle","year":"2015","unstructured":"Martin-Doyle, W., Leow, J. J., Orsola, A., Chang, S. L. & Bellmunt, J. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J. Clin. Oncol. 33, 643\u2013650 (2015).","journal-title":"J. Clin. Oncol."},{"key":"3025_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","volume":"60","author":"S van den Bosch","year":"2011","unstructured":"van den Bosch, S. & Alfred Witjes, J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur. Urol. 60, 493\u2013500 (2011).","journal-title":"Eur. Urol."},{"key":"3025_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk, M. et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in Situ). Eur. Urol. 81, 75\u201394 (2022).","journal-title":"Eur. Urol."},{"key":"3025_CR7","doi-asserted-by":"publisher","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","volume":"20","author":"TW Flaig","year":"2022","unstructured":"Flaig, T. W. et al. NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 2.2022. J. Natl Compr. Cancer Netw. 20, 866\u2013878 (2022).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"3025_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein, J. M. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J. Urol. 211, 533\u2013538 (2024).","journal-title":"J. Urol."},{"key":"3025_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.eururo.2020.02.012","volume":"78","author":"R Li","year":"2020","unstructured":"Li, R. et al. Systematic review of the therapeutic efficacy of bladder-preserving treatments for non-muscle-invasive bladder cancer following intravesical bacillus Calmette\u2013Gu\u00e9rin. Eur. Urol. 78, 387\u2013399 (2020).","journal-title":"Eur. Urol."},{"key":"3025_CR10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","volume":"83","author":"JP Jarow","year":"2014","unstructured":"Jarow, J. P. et al. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology 83, 262\u2013264 (2014).","journal-title":"Urology"},{"key":"3025_CR11","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M. et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J. Clin. Oncol. 34, 1935\u20131944 (2016).","journal-title":"J. Clin. Oncol."},{"key":"3025_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/BLC-159002","volume":"1","author":"SP Lerner","year":"2015","unstructured":"Lerner, S. P. et al. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bladder Cancer 1, 29\u201330 (2015).","journal-title":"Bladder Cancer"},{"key":"3025_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","volume":"12","author":"N Ramesh","year":"2006","unstructured":"Ramesh, N. et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor\u2013armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res. 12, 305\u2013313 (2006).","journal-title":"Clin. Cancer Res."},{"key":"3025_CR14","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","volume":"188","author":"JM Burke","year":"2012","unstructured":"Burke, J. M. et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J. Urol. 188, 2391\u20132397 (2012).","journal-title":"J. Urol."},{"key":"3025_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","volume":"36","author":"VT Packiam","year":"2018","unstructured":"Packiam, V. T. et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol. Oncol. 36, 440\u2013447 (2018).","journal-title":"Urol. Oncol."},{"key":"3025_CR16","unstructured":"FDA. BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry 1\u201310 (Office of Communications, Division of Drug Information, 2018)."},{"key":"3025_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar, A. V. et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 22, 919\u2013930 (2021).","journal-title":"Lancet Oncol."},{"key":"3025_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian, S. A. et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 22, 107\u2013117 (2021).","journal-title":"Lancet Oncol."},{"key":"3025_CR19","unstructured":"ImmunityBio announces FDA approval of ANKTIVA\u00ae, first-in-class IL-15 receptor agonist for BCG-unresponsive non-muscle invasive bladder cancer. ImmunityBio https:\/\/immunitybio.com\/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer\/ (2024)."},{"key":"3025_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","volume":"84","author":"PC Black","year":"2023","unstructured":"Black, P. C. et al. Phase 2 trial of atezolizumab in bacillus Calmette\u2013Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605. Eur. Urol. 84, 536\u2013544 (2023).","journal-title":"Eur. Urol."},{"key":"3025_CR21","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-23-0354","volume":"29","author":"R Li","year":"2023","unstructured":"Li, R. et al. A phase II study of durvalumab for bacillus Calmette\u2013Guerin (BCG) unresponsive urothelial carcinoma in situ of the bladder. Clin. Cancer Res. 29, 3875\u20133881 (2023).","journal-title":"Clin. Cancer Res."},{"key":"3025_CR22","unstructured":"Nadofaragene Firadenovec and Oportuzumab Monatox for BCG-Unresponsive, Non-muscle Invasive Bladder Cancer: Effectiveness and Value: Final Report (ICER, 2021)."},{"key":"3025_CR23","doi-asserted-by":"publisher","first-page":"S1343","DOI":"10.1016\/j.annonc.2023.10.111","volume":"34","author":"A Necchi","year":"2023","unstructured":"Necchi, A. et al. LBA105 results from SunRISe-1 in patients (Pts) with bacillus Calmette\u2013Gu\u00e9rin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy. Ann. Oncol. 34, S1343\u2013S1344 (2023).","journal-title":"Ann. Oncol."},{"key":"3025_CR24","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/JU.0000000000000688","volume":"203","author":"RL Steinberg","year":"2020","unstructured":"Steinberg, R. L. et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J. Urol. 203, 902\u2013909 (2020).","journal-title":"J. Urol."},{"key":"3025_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41585-021-00483-z","volume":"18","author":"R Li","year":"2021","unstructured":"Li, R., Zhang, J., Gilbert, S. M., Conejo-Garcia, J. & Mul\u00e9, J. J. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. Nat. Rev. Urol. 18, 543\u2013555 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"3025_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25\u201341 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"3025_CR27","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell, S. J., Peng, K.-W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658\u2013670 (2012).","journal-title":"Nat. Biotechnol."},{"key":"3025_CR28","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ccell.2020.12.022","volume":"39","author":"E Ramelyte","year":"2021","unstructured":"Ramelyte, E. et al. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. Cancer cell. 39, 394\u2013406.e4 (2021).","journal-title":"Cancer cell."},{"key":"3025_CR29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","volume":"18","author":"PK Bommareddy","year":"2018","unstructured":"Bommareddy, P. K., Shettigar, M. & Kaufman, H. L. Integrating oncolytic viruses in combination cancer immunotherapy. Nat. Rev. Immunol. 18, 498\u2013513 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"3025_CR30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109\u20131119.e10 (2017).","journal-title":"Cell"},{"key":"3025_CR31","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.22.00343","volume":"41","author":"JA Chesney","year":"2023","unstructured":"Chesney, J. A. et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J. Clin. Oncol. 41, 528\u2013540 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3025_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3233\/BLC-230056","volume":"9","author":"E Chang","year":"2023","unstructured":"Chang, E. et al. Advancing clinical trial design for non-muscle invasive bladder cancer. Bladder Cancer 9, 271\u2013286 (2023).","journal-title":"Bladder Cancer"},{"key":"3025_CR33","doi-asserted-by":"publisher","first-page":"EVIDoa2200167","DOI":"10.1056\/EVIDoa2200167","volume":"2","author":"K Chamie","year":"2023","unstructured":"Chamie, K. et al. IL-15 superagonist NAI in BCG-unresponsive non\u2013muscle-invasive bladder cancer. NEJM Evid. 2, EVIDoa2200167 (2023).","journal-title":"NEJM Evid."}],"updated-by":[{"DOI":"10.1038\/s41591-024-03137-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000}},{"DOI":"10.1038\/s41591-024-03157-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03025-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03025-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03025-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T10:07:46Z","timestamp":1724062066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03025-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3025"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03025-3","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41591-024-03137-w","asserted-by":"object"},{"id-type":"doi","id":"10.1038\/s41591-024-03157-6","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"assertion":[{"value":"5 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-024-03137-w","URL":"https:\/\/doi.org\/10.1038\/s41591-024-03137-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-024-03157-6","URL":"https:\/\/doi.org\/10.1038\/s41591-024-03157-6","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.L.: research support: Predicine; Veracyte; CG Oncology; Valar labs; scientific advisor\/consultant: BMS, Merck, CG Oncology, Iconovir; speaker bureau: Predicine; travel: Predicine, CG Oncology. T.S.: research support: GRAIL; scientific advisor\/consultant: Astellas, AstraZeneca, Pfizer, Seagen. E.M.U.: clinical trials: CG Oncology, Pfizer, Janssen, Merck, enGene; consultant: Pfizer, Janssen, Merck. D.M.G.: research support to institution: Genentech, Merck, Arvinas, Astellas, Harpoon Therapeutics; scientific advisor\/consultant: Pfizer, Exelixis, AstraZeneca, Seattle Genetics\/Astellas, Merck, BMS. J.M.J.: consulting: Pfizer, Janssen. J.J.M.: consultant: Merck, AstraZeneca, Incyte, Janssen, BMS, UroGen, Prokarium, Imvax, Pfizer, Seagen\/Astellas, Ferring; research funding: VHA, NIH, DoD; compensation for talks\/educational courses: AUA, OncLive, Olympus, UroToday; Clinical Trials: SWOG, Genentech, Merck, AstraZeneca; two patents: T1 and TCGA classifier. R.D.: consulting: CG Oncology, CIVCO, Ferring, ImmunityBio, Johnson & Johnson, Olympus; speaker: BMS, Uorgen. A.M.K.: grants: FKD Therapies (Ferring), PCORI, Photocure, Seagen, EnGene, Arquer Diagnostics, SWOG; consulting: Astellas Pharma, Biological Dynamics, BMS, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Imagin Medical, Imvax, Incyte, Janssen, Medac, Merck, Nonagen Bioscience, Pfizer, Protara Therapeutics, Roche, Seagen, Sessen Bio, Theralase, Urogen Pharma, US Biotest, Vivet Therapeutics; patent: CyPRIT. J.M.B.: CG Oncology consultant, former CMO, stock\/options; Kalivir CMO, stock options; Affyimmune consultant. K.A.K.: employee of CG Oncology, stock\/options. G.D.S.: clinical trial committee: Merck, BMS, Janssen, CG Oncology, Pfizer, Fidia, Seagen, Protara, EnGene Bio; consulting: CG Oncology, PhotoCure, Merck, Taris Biomedical (Now Janssen), Fidia Farmaceuticals, Urogen, Ferring, BMS, AstraZeneca, Pfizer, Janssen, Epivax Therapeutics, EnGene Bio, Astellas, SeaGen, Verity Pharmaceuticals, Protara, xCures, Nonagen, Nanology, Imvax, Asieris, UroViu, Aura Biosciences, Nucleix, Vesica Health; stock\/options: Epivax Therapeutics, CG Oncology, EnGene Bio, Vesica. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}